Press Releases

Date	Title	PDF Version
Oct 23, 2019	Alexion Reports Third Quarter 2019 Results
Oct 18, 2019	Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
Oct 16, 2019	Alexion to Acquire Achillion
Oct 10, 2019	Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer
Oct 10, 2019	Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
Oct 08, 2019	Alexion to Report Third Quarter 2019 Results On Wednesday, October 23, 2019
Sep 17, 2019	Alexion Announces CFO Succession
Sep 09, 2019	Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine
Sep 04, 2019	Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
Aug 28, 2019	Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Search